Creating a new protein to help develop an effective HIV vaccine
Manufacture a protein encoding CAP256.wk34.c80 OPT4 envelope for induction of V2 Apex bnAbs
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-11078959
This study is working on creating a new type of vaccine for HIV that uses tiny particles to help your body make strong antibodies, and it may involve patients in early tests to see how safe and effective it is.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11078959 on ClinicalTrials.gov |
What this research studies
This research focuses on manufacturing a specific protein that can induce broadly neutralizing antibodies (bnAbs) against HIV-1. The approach involves using nanoparticles to enhance the immune response to the HIV envelope protein, which is crucial for vaccine development. By optimizing the production of these proteins, the research aims to create a more effective vaccine that can elicit a strong immune response in humans. Patients may be involved in early-stage clinical trials to evaluate the safety and efficacy of this innovative vaccine approach.
Who could benefit from this research
Good fit: Ideal candidates for participation would include individuals at high risk for HIV infection or those who are HIV-negative and willing to participate in vaccine trials.
Not a fit: Patients who are already living with HIV and are seeking treatment for the virus may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a highly effective HIV vaccine that provides long-lasting immunity.
How similar studies have performed: Previous research has shown promise in using nanoparticle-based approaches for vaccine development, indicating that this method could be a viable strategy for HIV vaccine advancement.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAYNES, BARTON F. — DUKE UNIVERSITY
- Study coordinator: HAYNES, BARTON F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus